Asia's healthcare market has been growing and expanding, both through partnerships with U.S. life-sciences companies and through the region's establishment of biopharmaceutical scientific parks. As the world witnesses Asia's healthcare industries develop and mature, will the life-sciences firms in these emerging markets follow the same path as seen in the U.S.? How will different Asian countries employ different strategies to become globally competitive? What are some qualities - both cultural and professional - that will differentiate Asian biopharmaceutical firms with regards to their creativity and capabilities? With distinguished speakers from pharmaceutical companies, biotechnology firms, and government research institutes in Asia, the Healthcare panel will provide current trend and future outlook to the life-sciences industry in rising Asia.
CEO & President, PRARD Corporation
Tomoko Ohmae has spent more than 20 years for R&D activities in the pharmaceutical industry, involved in the development of US/European drug products in Japan at Japanese subsidiary of Syntex Corporation, and getting approvals on Japanese products in US/Europe at Japanese pharmaceutical company. With a background of Law and international work environment, Ms. Ohmae accumulated global aspects of regulatory knowledge and experience during her career. She started consulting in 2001 and decided to found her own consulting firm “PRARD Corporation” in 2006 to support Japanese and non‐Japanese clients for their international R&D projects.
Ms. Ohmae is a member of the Regulatory Affairs Professionals Society (RAPS), and the Organization for Professionals in Regulatory Affairs (TOPRA). She is a visiting lecturer at Tokyo Jikei Medical University. Ms. Ohmae received an L.L.B. from Kinki University, and completed the MBA Intensive‐course at Keio University.
President, Academia Sinica
Mr. Wong currently serves as President of Academia Sinica and Professor of Chemistry at Scripps Research Institute and National Taiwan University. He is also a current member of Board of Directors of National Science Council in Taiwan and the chief scientific advisor of Executive Yuan of Taiwan. Mr. Wong’s research interests are in the areas of bioorganic and synthetic chemistry and biocatalysis, including development of new synthetic chemistry for drug discovery. He is the author and co-author of over 600 publications, 60 patents, and four books (Enzymes in Synthetic Organic Chemistry, Combinatorial Chemistry in Biology, Catalysis from A to Z, and Carbohydrate-Based Drug Discovery.)
Mr. Wong is the recipient of numerous awards including the most recent 2008 FA Cotton Medal. He is also a member of the American Academy of Arts and Sciences and the US National Academy of Sciences among other prestigious organizations. Mr. Wong received his B.S. and M.S. degrees from National Taiwan University and Ph.D. in Chemistry from Massachusetts Institute of Technology. He worked at Harvard University as a postdoctoral fellow for a year, before becoming a professor at Texas A&M University and subsequently at Scripps Research Institute and National Taiwan University.
Head of Business Development & Licensing, Novartis Vaccines & Diagnostics
Sam Liao is the Asia Head of Business Development & Licensing for Novartis Vaccines & Diagnostics, Inc. He is responsible for the evaluation, negotiation, and execution of various commercial, licensing and co-development deals with international biotech companies and academics. He is also responsible for merger and acquisition activities and manages business alliances in Asia Pacific region.
Before joining Novartis, he was a Director of Corporate Development at Sanofi Pasteur, where he has over 15 years’ experiences working in the vaccine industry and held various positions in R&D, Marketing, Project Management and Strategic Planning. He has executed multiple deals worth more than $1 billion, and signed agreements with companies in North America, Europe, Japan and Australia. He was responsible for several high-profile government contracts with HHS, CDC and NIH, for SARS vaccine and pandemic avian influenza vaccine developments.
Sam Liao earned his medical degree from West China University of Medical Sciences, a Master’s degree on Biochemistry from University of Scranton, and an MBA from Columbia University.
President & CEO, Forma Therapeutics
Prior to joining FORMA, Steven Tregay was a Managing Director for the $200M Novartis Option Fund. He led the fund’s investments in and served on the Board of Directors of FORMA Therapeutics, Adenosine Therapeutics (sold: CLDA) and Cequent Pharmaceuticals. Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.
Stephen Knight (Moderator)
Managing Director, Fidelity Biosciences
Dr. Knight has worked in the pharmaceutical and biotechnology industries for over sixteen years. Prior to joining Fidelity in 2003, Dr. Knight was president and chief operating officer for EPIX Pharmaceuticals in Cambridge, Massachusetts. For six years before joining EPIX, Dr. Knight worked at Arthur D. Little Inc., primarily as a senior consultant in Cambridge and Brussels, Belgium specializing in mergers and acquisitions in the pharmaceutical industry. Prior to 1990, Dr. Knight performed research at AT&T Bell Laboratories (now Lucent Technologies), the National Institutes of Health, and at Yale University.
Dr. Knight holds an M.D. from the Yale University School of Medicine and an M.B.A. from the Yale School of Organization and Management. Dr. Knight received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.
Dr. Knight currently serves as Chairman of the Board of Directors for EnVivo Pharmaceuticals. He also serves on the Board of Directors of Ironwood Pharmaceuticals (formerly Microbia), CardioKine, Proteostasis Therapeutics, FoldRX, Bikam Pharmaceuticals, NextWave Pharmaceuticals, Ligocyte Pharmaceuticals and Respivert, Ltd.